ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASH--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUSÂź), today provided a business update and reported financial results for the three and six months ended June 30, 2025. Business Update Advanced development of TAEUS Liver. ENDRA advanced its product development work with enhancements to the TAEUS Liver systemâs probe design and proprietary algorithms, which are expected to deliver significantly improved accuracy and
Related Questions
What are the specific financial results for Q2 2025 (revenue, net profit/loss, cash flow, R&D expense) and how do they compare to the prior quarter and the same period last year?
How does the updated TAEUS Liver system's performance (accuracy, sensitivity, specificity) compare to competing ultrasoundâguided therapies and other minimally invasive liver treatment platforms?
When does ENDRA plan to commercialize the enhanced TAEUS Liver system, and what market share is it targeting in the liverâintervention market?
How will the improved probe design and proprietary algorithms impact the deviceâs cost structure and pricing strategy?
What is the anticipated impact of the development updates on cash burn, runway, and future financing needs?
What are the upcoming clinical trial milestones or data readouts for the TAEUS Liver system, and how will they affect the valuation?
How will this business update affect key valuation multiples (P/E, EV/EBITDA) and current analyst price targets?
Are there any partnership, licensing, or acquisition opportunities that could arise from the enhanced technology?
What are the key risks (regulatory, technical, competitive) if the enhanced TAEUS Liver system does not achieve the projected accuracy improvements?
What is the expected timeline for regulatory clearance (FDA, CE) for the enhanced TAEUS Liver system, and what milestones remain?